Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159742 · ClinicalTrials.gov registry record
Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases
A clinical trial of Neoplastic Disease, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT02159742 is a study of Neoplastic Disease that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 400 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02159742, a study of Neoplastic Disease, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
From 1996-present, we have used photodynamic therapy (PDT) to treat a number of neoplastic diseases both on prospective research protocols (for head and neck cancer, pleural malignancies, peritoneal carcinomatosis or sarcomatosis and prostate cancer) as well as for FDA approved and off label or compassionate exemption indications (neoplasms of the skin, bronchus, esophagus, head and neck and pleura). The goal of this treatment is to maximize quality of life and organ function while minimizing the chance of tumor recurrence. As such, we would like to retrospectively review the treatment parameters of all patients who undergo/underwent PDT (including operative notes and photodynamic therapy records) and treatment outcomes (including all organ functions, performance status, tumor recurrence, laboratory values and any other data present in the routinely documented follow up visits). For patients who have died or were lost to follow-up prior to initiation of this study, a retrospective review of available data will be performed. For patients who are still being actively followed after PDT or who receive PDT after the initiation of this study, informed consent will be obtained for obtaining continued follow-up data prospectively and any previous data will be collected retrospectively.. These subjects will continue to receive care from their current physicians according to standard medical practice and no attempt will be made to alter the types of follow-up, radiologic or other diagnostic studies or medical treatment as a result of enrollment in this study. All data will be de-identified and added to our already existing PDT treatment outcome databases for outcomes analysis, quality improvement and reporting of results in abstract and manuscript forms.
Conditions Studied
Interventions
- OTHER Data Collection
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2011-07 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159742
The ClinicalTrials.gov registry entry for NCT02159742 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplastic Disease appearing as the primary indexed condition, and to 1 intervention - of which Data Collection is the first listed.
NCT02159742 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02159742 about?
NCT02159742 is a clinical study titled "Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases". From 1996-present, we have used photodynamic therapy (PDT) to treat a number of neoplastic diseases both on prospective research protocols (for head and neck cancer, pleural malignancies, peritoneal carcinomatosis or sarcomatosis and prostate cancer) as well as for FDA approved and off label or comp...
What is the current status of trial NCT02159742?
This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2011-07. Estimated completion is 2027-12.
What conditions does trial NCT02159742 study?
This clinical trial studies the following conditions: Neoplastic Disease.
What interventions are being tested in trial NCT02159742?
The interventions under investigation include: Data Collection (OTHER).
Who is sponsoring clinical trial NCT02159742?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02159742 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplastic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.